Coffee and Parkinson's disease
Abraham Olufemi Asuku1, Maryam Tayo Ayinla2, Tobiloba Samuel Olajide3
1Bioresources Development Centre, National Biotechnology Research and Development Agency, Ogbomoso, Oyo, Nigeria; Department of Physiology, Faculty of Basic Medical Sciences, College of Health Sciences, University of Ilorin, Ilorin, Kwara, Nigeria.
Progress in Brain Research
|August 21, 2024
Summary
Coffee consumption may offer neuroprotection against Parkinson's disease (PD). Compounds in coffee, like caffeine, may reduce PD incidence and symptoms by impacting alpha-synuclein and the gut microbiome.
Area of Science:
- Neuroscience
- Pharmacology
- Gastroenterology
Background:
- Parkinson's disease (PD) involves dopaminergic neuron loss and alpha-synuclein aggregation, causing motor and cognitive deficits.
- Current treatments for PD are limited in halting disease progression.
- Epidemiological data suggests coffee consumption is linked to reduced PD incidence.
Purpose of the Study:
- To review the neuroprotective effects of coffee in Parkinson's disease.
- To explore coffee's bioactive compounds and their mechanisms against alpha-synuclein.
- To examine the role of the gut microbiome in coffee's anti-Parkinsonian effects.
Main Methods:
- Literature review of epidemiological studies and experimental research.
- Analysis of coffee's bioactive constituents, including caffeine, chlorogenic acid, and cafestol.
- Investigation of the microbiota-gut-brain axis in relation to PD and coffee.
Main Results:
- Caffeine and other coffee compounds exhibit neuroprotective properties against PD.
- Coffee consumption correlates with lower PD incidence, potentially due to caffeine's effects.
- Coffee intake influences gut microbiota composition, potentially mitigating inflammation and protein misfolding.
Conclusions:
- Coffee and its constituents show promise in managing Parkinson's disease symptoms and progression.
- The gut microbiome-modulating effects of coffee represent a potential therapeutic avenue for PD.
- Further research into coffee's components and the microbiota-gut-brain axis is warranted for PD treatment strategies.
Related Concept Videos
01:24Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
01:15Parkinson's Disease: Overview
500
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
500
01:37Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:19Psychoneuroimmunology: Diabetes and Cancer
27
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
27